Precision BioSciences posted a wider net loss in Q3 2025, driven by minimal revenues and continued R&D investment. The company maintains a cash position of over $71 million and anticipates progress on its PBGENE programs into 2026.

Precision BioSciences posted minimal revenue for Q1 2025 while advancing its lead in vivo gene editing programs. The company reported a net loss of $20.6 million and emphasized its strong cash position and progress in clinical trials for PBGENE-HBV and PBGENE-DMD.

The company reported a significant decline in Q4 2024 revenues compared to the previous year, accompanied by increased research and development expenses as clinical activities accelerated. Net losses expanded, reflecting operational investments and decreased collaboration revenues.

Precision BioSciences reported total revenues of $0.6 million for the quarter ended September 30, 2024, compared to $13.1 million for the same period in 2023. Net loss from continuing operations was $16.4 million for the quarter ended September 30, 2024, as compared to a net loss from continuing operations of $12.1 million for the same period in 2023. As of September 30, 2024, Precision had approximately $121.3 million in cash, cash equivalents, and restricted cash.